Alpine Immune Sciences (NASDAQ:ALPN) Sets New 1-Year High at $64.70

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) hit a new 52-week high on Monday . The stock traded as high as $64.70 and last traded at $64.70, with a volume of 1290129 shares changing hands. The stock had previously closed at $64.56.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ALPN shares. Wolfe Research reiterated a “peer perform” rating on shares of Alpine Immune Sciences in a report on Thursday, April 11th. HC Wainwright lowered shares of Alpine Immune Sciences from a “buy” rating to a “neutral” rating in a report on Thursday, April 11th. SVB Leerink lowered shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating and upped their price objective for the company from $42.00 to $65.00 in a report on Friday, April 12th. Morgan Stanley reiterated an “equal weight” rating and set a $65.00 price objective (up previously from $47.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $65.00 price objective (up previously from $41.00) on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Eight analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $50.33.

Alpine Immune Sciences Trading Up 0.2 %

The firm’s 50-day moving average price is $43.56 and its 200 day moving average price is $26.85.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its quarterly earnings data on Monday, March 18th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The business had revenue of $30.85 million during the quarter, compared to the consensus estimate of $6.90 million. On average, research analysts anticipate that Alpine Immune Sciences, Inc. will post -1.74 EPS for the current year.

Institutional Investors Weigh In On Alpine Immune Sciences

A number of institutional investors have recently added to or reduced their stakes in ALPN. Allspring Global Investments Holdings LLC grew its position in Alpine Immune Sciences by 745.5% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,312 shares in the last quarter. AJOVista LLC bought a new stake in Alpine Immune Sciences in the 4th quarter worth about $64,000. Barclays PLC grew its position in Alpine Immune Sciences by 44.3% in the 3rd quarter. Barclays PLC now owns 9,126 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 2,801 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Alpine Immune Sciences by 411.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,490 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 4,417 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its stake in Alpine Immune Sciences by 75.8% in the third quarter. New York State Common Retirement Fund now owns 9,634 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 4,155 shares during the last quarter. 75.17% of the stock is owned by institutional investors.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.